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Abstract
Background: Neoadjuvant therapy is increasingly the standard of care in the management of locally advanced
adenocarcinoma of the oesophagus and junction (AEG). In randomised controlled trials (RCTs), the MAGIC regimen
of pre- and postoperative chemotherapy, and the CROSS regimen of preoperative chemotherapy combined with
radiation, were superior to surgery only in RCTs that included AEG but were not powered on this cohort. No completed
RCT has directly compared neoadjuvant or perioperative chemotherapy and neoadjuvant chemoradiation. The Neo-AEGIS
trial, uniquely powered on AEG, and including comprehensive modern staging, compares both these regimens.
Methods: This open label, multicentre, phase III RCT randomises patients (cT2-3, N0-3, M0) in a 1:1 fashion to receive
CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks). The power
calculation is a 10% difference in favour of CROSS, powered at 80%, two-sided alpha level of 0.05, requiring 540 patients
to be evaluable, 594 to be recruited if a 10% dropout is included (297 in each group). The primary endpoint is overall
survival, with a minimum 3-year follow up. Secondary endpoints include: disease free survival, recurrence rates, clinical
and pathological response rates, toxicities of induction regimens, post-operative pathology and tumour regression
grade, operative in-hospital complications, and health-related quality of life. The trial also affords opportunities
for establishing a bio-resource of pre-treatment and resected tumour, and translational research.
Discussion: This RCT directly compares two established treatment regimens, and addresses whether radiation
therapy positively impacts on overall survival compared with a standard perioperative chemotherapy regimen
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Background
Adenocarcinoma of the oesophagus and the oesopha-
gastric junction (AEG) have markedly increased in in-
cidence in the West over the last 30 years [1–3]. AEG
tumours have been defined topographically by Siewert
et al., with true oesophageal (AEG I) tumours arising
in a background of reflux-induced specialised intes-
tinal metaplasia, AEG II representing true cardia tu-
mours, and AEG III denoting gastric tumours within
5 cm below the cardia and involving the junction [4].
The disease is often advanced at presentation, and the
overall 5-year survival is very poor at between 10–
20% [1]. For patients presenting with localised dis-
ease, several advances in standards of care have
emerged in recent years which have improved disease
management and survival, with an approximate 5-
year survival of 35 to 50% for patients who can be
treated with curative intent. First, comprehensive sta-
ging with computed tomography-18FDG positron
emission tomography (PET-CT) and endoscopic
ultrasound (EUS) has improved selection of patients
for curative treatment [1, 5]. Second, the increasing
centralisation of care within high-volume hospitals
has increased focus on all aspects of quality assur-
ance, with associated improvements in oncological
and operative outcomes [6]. Finally, via a number of
randomised controlled trials (RCTs), neoadjuvant and
adjuvant therapies have been established as superior
to surgery alone, and are increasingly the standard of
care for locally advanced disease [7].
There are four key RCTs evaluating neo-adjuvant or
perioperative chemotherapy compared with surgery
alone. The RTOG 8911/Intergroup 0113 RCT rando-
mised 440 patients, 54% with adenocarcinoma, to pre-
and postoperative 5-Fluorouracil (FU) and cisplatin
(Cis), and compared this regimen with surgery alone.
No improvement in survival was evident [8, 9]. A
similarly powered study of 802 patients conducted by
the Medical Research Council in the UK, the OEO2
Trial, where 66% of patients had adenocarcinoma,
randomised patients to two cycles of pre-operative Cis
and FU, or surgery alone, and reported a significantly
improved survival at 5 years [23% compared with 17%
(p = .03)] [10, 11]. The Medical Research Council
Adjuvant Gastric Infusional Chemotherapy (MAGIC)
trial of 503 patients, although powered for gastric
adenocarcinoma, included 11% with junctional and
14% with lower oesophageal adenocarcinoma, and
compared 3 cycles of epirubicin, Cis and FU (ECF) be-
fore and after surgery with surgery alone [12]. The 5-
year survival rate was 36% for combined modality
therapy compared with 23% for patients with surgery
alone (p = 0.009). The French ACCORD-07 provided
similar results, recruiting 224 of a planned 250
patients, with 64% having junctional adenocarcinoma,
and 11% with lower oesophageal adenocarcinoma [13].
Cis and FU was administered before and after (in re-
sponders) surgery, and the 5 year survival was 38% for
combination therapy compared with 24% for surgery
alone (p = 0.02). Accordingly, the MAGIC and AC-
CORD trials provide a significant level of evidence for
perioperative chemotherapy in adenocarcinoma of the
lower oesophagus and junction compared with surgery
alone. Moreover, a new dimension was provided
through the United Kingdom National Cancer Re-
search Institute REAL2 trial [14]. This multicentre
trial of patients with advanced inoperable or recurrent
disease, using a 2×2 randomisation, showed the non-
inferiority of substituting oral capecitabine (X) for
infused FU, and oxaliplatin (O) for Cis, in the ECF
regimen, with oxaliplatin associated with lower incidences
of grade 3 or 4 neutropenia, renal toxicity and thrombo-
embolic side effects.
Up to the recent publication of the CROSS trial,
the interpretation of trials of combination chemother-
apy and radiation therapy prior to surgery, and meta-
analysis, was more difficult compared with trials using
chemotherapy alone, for several reasons, including
small underpowered studies, a mix of pathological
types, variation in dose and fractionation across stud-
ies, inadequate pre-treatment staging, and poor out-
comes in surgical only cohorts. In the CROSS trial
(Chemoradiotherapy for Esophageal Cancer followed
by Surgery Study), 366 patients, 75% with adenocar-
cinoma, were randomised to multimodal therapy (pac-
litaxel, carboplatin and 41.4 Gy/23 fractions) or
surgery alone [15]. The median overall survival (OS)
was 49 months in the multimodality arm compared
with 24 months for surgery alone (p = 0.003), with a
corresponding 5-year OS rate of 47% in the multi-
modality arm compared with 34% in the surgery co-
hort. The neoadjuvant regimen was completed by 162
(95%) of 171 patients, with a low recurrence of grade
3 or adverse effects [29 (17%) of 171 patients). Side-
effects were few, 13 (8%) had grade 3 or worse haem-
atological toxicity, and 18 (11%) had grade 3 or worse
non-haematological toxicity. The R0 resection rate,
reflecting complete surgical resection and negative
margins, was 92% in the multimodality arm compared
with 69% in the surgery only arm. Longer follow up
showed reduced locoregional recurrences in the treat-
ment arm, and to a lesser extent reduced systemic re-
currences [16, 17]. At this time, accordingly, the
CROSS trial provides strong support for the evidence-
base supporting preoperative chemoradiation in
oesophageal cancer, which, notwithstanding its wide-
spread use, was somewhat inconsistent from earlier
RCTs [18–21].
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Studies comparing pre-or perioperative chemother-
apy with preoperative chemoradiation are lacking.
The Preoperative Chemotherapy or Radiochemother-
apy in Esophagogastric Adenocarcinoma Trial
(POET) is the only phase III RCT to address this
question, where 119 patients with EUS staged (uT3-
4, Nx, Mo) adenocarcinoma (AEG 1and II) received
either preoperative induction chemotherapy (Cis, FU
and leucovorin) or induction chemotherapy followed
by chemoradiation (Cis and etoposide with 30Gy in
15 fractions of radiation therapy [RT]), and then sur-
gery [22]. The trial was closed prematurely due to
slow accrual, with 3 year survival in the multimodal
arm of 47.4% compared with 27.7% in the chemo-
therapy arm (p =0.07.) However, the pathological
complete response rate was significantly (15.6% vs
2% p = 0.03) improved with the addition of radiation,
and consistent with other trials comparing multi-
modal therapy with surgery alone, the pathological
node negative rate was significantly decreased (64.4%
vs 37.7%; p =0.01).
The excellent results reported for the CROSS trial
define this currently as the multimodal standard of care
for oesophageal cancer, and the modified MAGIC
regimen, chosen for comparison in Neo-AEGIS, is in
common use in the UK and Europe for junctional
adenocarcinoma. The Neo-AEGIS trial accordingly
will compare regimens which have provided Level I
evidence of their superiority compared with surgery
alone, albeit not in trials focused exclusively on
adenocarcinoma of the oesophagus and junction. The
proposed trial will be unique in also including AEG
type III in addition to AEG types I and II, this being
enabled by the recent AJCC/UICC 7th edition staging
of all junctional tumours as oesophageal, and harmo-
nising nodal staging (N1-3) across what was formerly
different nodal staging for oesophageal (AEG I and
II) and gastric (AEG III)-derived adenocarcinoma
[23]. The trial will also be the first to include CT-
PET as the uniform standard baseline staging modal-
ity, as well as embedded quality assurance for deliv-
ery of RT.
Methods and Design
Study design (Fig. 1)
Neo-AEGIS is a multicentre phase III open-labelled,
randomised controlled trial. Eligible patients will be ran-
domised in a 1:1 fashion between the modified MAGIC
regimen (ECF/ECX or EOF/EOX) or the multimodality
therapy (CROSS protocol), the latter with a modernised
design and delivery of radiation therapy. The aim of this
study is to compare the two Level-1 evidence based
Fig. 1 Schedule of enrolment, interventions, and assessments
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regimens exclusively in patients defined as high-risk for
relapse. High-volume (i.e. > 30 resections per year) cen-
tres or nationally designated oesophageal cancer surgery
centres will participate.
Study objectives
The primary objective is to evaluate overall survival,
calculated from the date of randomisation and an
event registered on the date of death from any cause.
Secondary objectives include the effect of both neoad-
juvant regimens on clinical response rate (relief of
dysphagia, improvement in health related quality of
life, endoscopic regression, radiological response),
tumour regression grade, surgical resection rate,
pathological R0 resection, post-operative pathology
including nodal involvement, disease-free survival,
time to treatment failure, site of treatment failure,
and toxicity. Toxicity of treatment will be graded ac-
cording to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 4.0 [24]. All post-operative complications will
be captured for up to 90 days after surgery and
graded according to the Clavien-Dindo classification
system, and the Esophageal Complications Consensus
Group (ECCC) consensus on standardisation of data
collection for complications associated with oesopha-
gectomy [25].
Patient selection
Patients with histologically proven adenocarcinoma of
the oesophagus or oesophago-gastric junction will
undergo preoperative staging with endoscopy, and
CT-PET. EUS will be performed in all cases except
where near-complete dysphagia precludes assessment,
and laparoscopy is recommended for locally advanced
intra-abdominal disease. Patients, with pre-treatment
clinical stage cT2-3, N0-3, M0, and tumours less
than 8 cm in length, will be assessed for suitability
for inclusion to this trial. Requirements include an
ECOG performance status 0-2; an adequate absolute
neutrophil count (ANC) >1.5x109/l; white blood cell
count > 3x109/l; platelets > 100x109/l; haemoglobin
(Hb) > 9 g/dl (can be post-transfusion); a glomerular
filtration rate > 60 ml/min calculated using the
Cockcroft-Gault Formula; and serum bilirubin <1.5x
Upper Limit of Normal (ULN); AST <2.5x ULN and
ALP <3x ULN (ULN as per institutional standard);
and adequate respiratory function, including an
FEV1 > 1.5 L. For all patients an ejection fraction of
greater than 50% is required, assessed by either echo-
cardiogram or MUGA scan. Patients with a signifi-
cant cardiac history (e.g. known ischemic disease,
cardiomyopathy) must have in addition cardiac clear-
ance by a cardiologist. In addition to exclusions
based on not meeting above criteria, prior abdominal
or thoracic radiotherapy, chemotherapy for gastro-
intestinal cancer, peripheral neuropathy, known HIV
or other malignancies within 5 years are also exclu-
sion factors.
Treatment regimens
Arm A – Modified Magic Chemotherapy Regimen
The regimen consists of 3 pre- and 3 postoperative
cycles of RCF/ECX or EOF/EOX. Each cycle of
chemotherapy lasts 21 days/3 weeks. The drugs used
in the modified MAGIC regimen include Epirubicin
intravenously (IV) (50 mg/m2; day 1), Cisplatin IV
(60 mg/m2 with concurrent 500 ml 10% mannitol IV,
day 1) or Oxaliplatin IV (130 mg/m2 day 1) and 5-
Fluorouracil IV (200 mg/m2/d × 3 weeks)/or Capecita-
bine 625 mg/m2 twice daily for 3 weeks orally. The
choice between administering Cisplatin or Oxaliplatin
and 5 Fluorouracil or Capecitabine is at the discretion
of the investigator.
Arm A: Modified MAGIC Regimen
Drug Dose Administration Days Given
Epirubicin 50 mg/m2 Slow IV push into the side arm of NaCl 0.9% drip Day 1
Cisplatin with hydration - mannitol 10%* 60 mg/m2 Dilute in NaCl 0.9%.
500 mls Administer over 2 h.
OR Infuse concurrently with cisplatin over 2 h Day 1
Oxaliplatin 130 mg/m2 Dilute in Dextrose 5%.
Administer over 2 h
5-Fluorouracil 200 mg/m2/d Given at a dose of 200 mg/m2/day by continuous
infusion every day for 21 days/3 weeks
Daily for 21 days/3 weeks
OR
Capecitabine 625 mg/m2 twice daily Taken orally twice daily for 21 days Daily for 21 days/3 weeks
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Arm B – CROSS protocol, Multimodal arm: Chemotherapy
and Radiotherapy Regimen
Arm B consists of the multimodal arm, which includes a
combination of chemotherapy and radiotherapy prior to
surgery. The patient will receive 4 and a half weeks of
radiation therapy (41.4 Gy/23 fractions/1.8 Gy per frac-
tion) and 5 weekly cycles of chemotherapy. RT is admin-
istered on days 1-5, days 8-12, days 15-19, days 22-26
and days 29-31 inclusive. The patient will receive 5 cycles
of chemotherapy, Paclitaxel 50 mg/m2 and Carboplatin
Area Under Curve (AUC) =2 (calculated using the Cal-
vert formula [26]), given by IV infusion on days
1,8,15,22, and 29.
Arm B: Chemotherapy
Radiotherapy
A planning CT scan will be performed following random-
isation with intravenous contrast injection (providing ad-
equate renal function). Patients will fast for 2 h and then
drink 200mls of liquid 30 min prior to CT planning and
prior to each treatment in an attempt to reproduce the
same anatomical position of the stomach throughout treat-
ment. Patients will be scanned and treated, in the supine
position with arms above their head, knee support, and im-
mobilisation with thermoplastic device or vacuum cushion
as per local protocols. The scan will fully include target
and all organs at risk (lungs, liver, kidneys and stomach).
Diagnostic information for the purpose of defining the
target volume will be taken from the diagnostic CT scan,
EUS (referenced to CT identifiable structure) and PET/
CT. Target volume definition (TVD) will be divided into
(i) middle third - defined here as primary tumour epi-
centre between 24 cm and 32 cm ab oral, and (ii) lower
third and oesophagogastric junction (Siewert types AEG I-
III) - defined here as primary tumour epicentre from
32 cm ab oral to sub-cardia, which is expected represent
the vast majority of cases in this trial. Where the passage
of the EUS scope across the tumour has not been possible,
findings from diagnostic endoscopy and PET imaging will
be used to define the disease centre.
TVD is described in detail in the protocol along with a
contouring atlas. In brief: The gross tumour volume
(GTV) consists of the gross tumour (GTVT) and re-
gional malignant lymph nodes (GTVN). GTVT and
GTVN include the entire circumference of the
oesophagus, and are combined without a margin to form
GTVTN using the Treatment Planning System (TPS).
The clinical target volume (CTV) is made up of the
GTV including a margin for occult disease. There are
three CTVs in this protocol, CTVA, CTVB and
CTVCOMB. CTVA is defined by an isotropic margin of
0.5 cm around GTVTN. CTVB will comprise of the ‘fat
pad’ around the oesophagus. The ‘fat pad’ is contoured
at the same levels as the GTVTN, for 3 cm superior and
inferior to GTVT. Thus, CTVB encompasses the entire
GTV with a cranio-caudal margin to account for occult
submucosal spread of tumour. The ‘fat-pad’ is encom-
passed to cover subclinical nodal disease. The Planning
Target Volume (PTV) is created using the TPS via the
expansion of CTVCOMB by an isotropic margin of
10 mm (5 mm IM and 5 mm SM), in all dimensions.
Below the junction GTVT does not include the entire
circumference of the stomach at the level of disease, but
just the gross tumour. Where GTVN includes nodes in
the abdomen, CTVB is extended to include that entire
nodal station. No other abdominal nodal stations will be
electively included. Spinal Cord, Spinal Cord PRV (plan-
ning organ at risk volume) Lungs Heart, Liver and both
Kidneys are delineated as Organs at risk (OARs). Dose-
volume histograms of these structures will be obtained
for all patients. Where possible, the volume of both
lungs that receive 20Gy or more will not exceed 25% of
combined lung volume (V20Gy lung < 25%). The volume
of the heart that receives 40Gy will not exceed 30% of
the heart volume (V40Gy heart < 30%) and volume of
heart that receives 25Gy will not exceed 50% of the heart
volume (V25Gy heart < 50%) (these are optimal objec-
tives – to be achieved where possible but at lower prior-
ity than other objectives). The volume of the liver that
receives 30Gy will not exceed 30% of the total liver vol-
ume (V30Gy liver < 30%). The maximum dose to the
spinal cord may not exceed 45Gy (Dmax (0.03 cc) < =
45Gy). The maximum dose to 1 cm3 of the spinal cord
PRV may not exceed 40Gy (D1cm3 < 40Gy). If the PTV
lies close to or overlaps with the Spinal Cord PRV, the
treating clinician may discretionally allow a point max-
imum dose up to 45Gy. Alternatively, they may report a
PTV compromise.
A single-phase coplanar 3D-conformal treatment plan
will be calculated on the planning CT scan, tailored to
achieve optimal PTV coverage while respecting the dose
volume constraints. The plan will typically be delivered
Drug Dose Administration Details Days Given
Dexamethasone 10 mg Give IV half an hour before
commencing Paclitaxel
Days 1, 8, 15,
22 and 29
Chlorphenamine 10 mg Give IV half an hour before
commencing Paclitaxel
Days 1, 8, 15,
22 and 29
Ranitidine 50 mg Give IV half an hour before
commencing paclitaxel
Days 1, 8, 15,
22 and 29
Paclitaxel 50 mg/m2 The total calculated dose
of paclitaxel, infused over
1 h IV (PVC free).
Days 1, 8, 15,
22 and 29
Ondansetron 8 mg Administer orally half an
hour before carboplatin
Days 1, 8, 15,
22 and 29
Carboplatin Area
Under Curve =2
As per
Calculation
The total calculated dose
of carboplatin, infused
over 1 h IV.
Days 1, 8, 15,
22 and 29
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from 3–5 gantry angles (though the number of gantry an-
gles is not mandated) and utilize only megavoltage photon
energies. The treatment fields will conform to the target
via the use of multileaf collimators. Megavoltage photon
energies ≥ 6MV is mandatory. The use of cone beam CT
matched to planning CT scans is mandatory within this
study. 4D planning will be encouraged within the Neo-
AEGIS trial but is not mandated.
A meticulous Radiotherapy Quality Assurance (RTQA)
programme has been developed for the Neo-AEGIS trial.
Pre-trial RTQA Procedures are as follows: All centres
who wish to participate in Neo-AEGIS must satisfactor-
ily complete a pre-accrual outlining benchmark case of a
mid and lower oesophageal cancer case. Outlines will be
compared against a consensus reference volume. Each
centre must submit a satisfactory plan for a pre-outlined
patient. A Radiotherapy Process Document must be pro-
duced describing technical details of all trial patient pro-
cesses for that centre. For on-trial RTQA, radiotherapy
should commence within 15 days of signing consent,
meaning that prospective/real-time review is not prac-
tical. Instead, there will be timely-retrospective review of
the outline and plan for the first patient case from each
centre (the RTQA team will give feedback to the centre
within 2 weeks of the start of treatment). A second case
will also be reviewed should there have been an issue
with the first case. A random allocation of 10% of all
outlines and plans will be submitted from all centres for
timely-retrospective review as above. This will be the
responsibility of each national Radiotherapy Principal
Investigator (PI) [Brian O’Neill (Irl); Tom Crosby (UK),
Kenneth Hofland (Dk)].
Adverse Events (AE)
Adverse events will be recorded on the Adverse Event
case report form and must be graded using the National
Cancer Institute's Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 4.0 [24]. All non-
serious and serious AE occurring in each patient will be
reported up to 30 days after the last dose of study drug
has been received. The last dose of study drug is defined
as the last dose of study drug the patient receives during
the last post-surgery chemotherapy cycle (ARM A) and
the last dose of chemotherapy or radiation therapy the
patient receives prior to the scheduled surgery (ARM B).
Postoperative complications up to 90 days will be re-
ported separately.
Surgery
The operation will be performed between 3 and 10 weeks
following completion of neoadjuvant therapy. Radical
en-bloc resection around the tumour as well as a re-
gional lymphadenecomy is the operative goal, however,
approaches may vary depending on tumour location and
institutional preference and may include en-bloc trans-
thoracic, both 2 and 3 stage, with 2-field lymphadenec-
tomy, minimally invasive oesophagectomy or hybrid
approaches, transhiatal approaches, and an extended
total gastrectomy and abdominal lymphadenectomy for
AEG type III junctional tumours. All post-operative
complications will be recorded on the case report form
for up to 90 days after surgery. The highest severity
complication will be graded according to the Clavien-
Dindo classification system and the recent International
Consensus on Standardization of Data Collection for
Complications, agreed by the Esophageal Complications
Consensus Group [25, 26].
Pathology
Pathological assessment is performed as per standard
guidelines and is based on the UICC/TNM 7th edition
(2010) [23]. In patients treated with neo-adjuvant ther-
apy, the extent of residual carcinoma in the oesopha-
gectomy specimen will be assigned to one of five
categories as per Mandard et al [27]. TRG1 represents a
complete response (pCR); TRG2 represents rare residual
cancer cells scattered throughout the fibrosis; TRG3 rep-
resents an increase in the number of residual cancer
cells, but fibrosis still predominate, TRG4 represents re-
sidual cancer cells outgrowing fibrosis and TRG5 repre-
sents a complete absence of regression change. The
lymph node dissection should contain at minimum 15
nodes. The circumferential resection margins (R status)
will be determined by both the residual tumour classifica-
tion system outlined by the Royal College of Pathology
(RCP) (R1 denotes tumour < 1 mm) from margin, and the
College of American Pathologists (CAP) classification
where R1 denotes actual margin involvement [28, 29].
Follow-up
An initial post-operative visit will occur within 2 weeks
-1 month post-discharge from hospital post- surgery, or
sooner as patients’ condition determines. After the initial
post -operative visit to the surgical team, the patient in
Arm A will be assessed for adjuvant chemotherapy and
will be referred back to the treatment oncologist for
completion of treatment. Follow up visits with the trial
centre will occur at 3 months, 6 months, 9 months and
12 months for the 1st year and 6 monthly thereafter or
until progression of disease is documented or death,
whichever occurs earlier. CT or CT-PET scan (as per in-
stitutional standard practice) will be carried out 1 year
post operatively or earlier if deemed clinically necessary
as per surgeon and annually thereafter. Recurrence of
disease should be documented by appropriate imaging
and biopsies where appropriate.
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Statistical analysis
The study primary end point is overall survival. The study
design is with a two-sided alpha level of 0.05, and an esti-
mated 80% power to detect -year increase in overall sur-
vival of 10% i.e. 43% to 53%, through the use of the
CROSS protocol, and with initial evaluation at 3 years of
follow up of the last patient. A two-sided log rank test
with an overall sample size of 594 subjects (of which 297
are in group 1 and 297 are in group 2) achieves 80%
power at a 0.05 significance level to detect a differ-
ence of 0.10 between 0.43 and 0.53-the proportions
surviving in groups 1 and 2, respectively. This corre-
sponds to a hazard ratio of 1.55. The data will be
analysed three years after the last patient enters the
study. The proportion of non-evaluable patients is as-
sumed to be 10%. These results are based on the as-
sumption that the hazard rates are proportional.
Recruitment will occur over 5 years.
Disease-free survival will be calculated from randomization
to the first event (i.e. local recurrence or progression,
distant recurrence, or death from any cause), and over-
all survival will be calculated from randomization to
death. Kaplan-Meier curves for disease-free and overall
survival will be compared with the use of the log-rank
test on an intention to treat basis. Hazard ratios will be
calculated with the use of a Cox regression model in-
cluding treatment alone (primary analysis) and after ad-
justment for prognostic factors of interest. Categorical
data will be compared with the use of chi-squared tests,
with a test for trend over ordered categories (T, N, etc).
Tumour measurements will be compared with the use of
appropriate parametric t-tests or nonparametric Mann-
Whitney tests. All tests will be two sided. The primary
analysis will be performed on an intention to treat (ITT)
basis, that is, for all patients randomised into the study, re-
gardless of whether they received treatment or what treat-
ment they received. A per-protocol analysis, excluding
patients who did not sufficiently comply with the protocol
(in terms of exposure to treatment, availability of mea-
surements and major protocol violations) will supplement
the ITT analysis as a secondary analysis.
Interim futility analyses will be based on the rule of
Freidlin et al with a Linear 20% Inefficacy Boundary
(LIB20) [30]. This rule provides the opportunity to ter-
minate early for evidence that the experimental arm will
not prove superior, but protects against aggressive early
termination for treatment effect sizes smaller than
planned. To allow for the situation in which the experi-
mental treatment is nontrivially less efficacious than
the control arm, there will be an early ‘harm’ look
based on 25% of events (deaths), followed by two fur-
ther interims based on 40% and 70% of information.
The results of the futility analyses will be reported to
the DSMB.
Ethical and regulatory considerations
The trial has been submitted and approved by a multi-
centre research ethics committee in each of the participat-
ing countries, and received clinical trials authorisations
from regulatory authorities. This trial was approved by the
joint research ethics committee of Tallaght Hospital/St
James’ Hospital (REC reference: 2016-02 List 5 [11]). The
study will be conducted in accordance with ethical princi-
ples founded in the Declaration of Helsinki [31]. In each
centre, the lead investigator will be responsible for identi-
fication, recruitment, data collection, completion of case
report forms, follow-up of study patients and adherence
to study protocol. Informed consent will be obtained from
participants by the local lead investigator using a standar-
dised consent form and participant information sheet
(Additional file 1: Appendix A). A trial steering committee
(TSC) is responsible for the day-to-day running of the trial
(composition: Additional file 2: Appendix B), and an inde-
pendent data and safety monitoring board (DSMB) with
no competing interests has been appointed to review the
trial approximately every 6 months. An interim analysis is
planned after recruitment of approximately 200 patients,
at the discretion of the DSMB. The Chief Investigator
(JVR) is responsible for the design and conduct of Neo-
AEGIS, and in combination with the project team in
ICORG is responsible for the preparation of protocol and
revisions, preparation of investigators literature and case
report forms, and organization of steering committee
meetings. ICORG is responsible for study planning, data
master file, data verification and randomization. Random-
isation will be generated via a computer-generated ran-
dom numbers sequence without stratification. Upon
completion of the enrolment form, the allocation will be
generated via contacting ICORG. The TSC are responsible
for agreement of the final protocol and any revisions.
Revisions are communicated to all lead investigators via
the TSC. All lead investigators are members of the TSC
and one lead investigator per country is nominated as na-
tional coordinator. Authorship will be defined as per
International Committee of Medical Journal Editors
guidelines [32]. Results will be communicated at relevant
international conferences, via publication and on the clin-
ical trial registry. Data are collected using the individual
trial case number on standard case report forms collated
centrally by ICORG and personal information will not be
individually identifiable. The final trial dataset will be
available to study investigators but will not be analysed
per centre.
Withdrawal criteria
Treatment delay beyond 3 weeks is acceptable for treat-
ment related toxicity, in which case a delay of up to
6 weeks is permitted before treatment is considered in-
tolerable and the patient is withdrawn. Other situations
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where a study treatment may need to be interrupted for
other clinical reasons will be considered. However, if an
interruption of study treatment of more than 3 weeks is
anticipated, the study chief investigator will be notified
in advance, and further advice sought with regards to
the appropriateness of restarting study treatment. Other
criteria for which treatment will be withdrawn include:
disease progression before completion of study treat-
ment; withdrawal of consent for treatment and/or study
participation; unacceptable treatment-related toxicity or
adverse events as judged by either the patient’s treating
physician or the Chief Investigator; pregnancy; and pa-
tient non-compliance.
Discussion
The most recent updated meta-analysis of RCTs for
oesophageal cancer, published in 2011, and including the
CROSS trial, concludes that “a clear advantage of neoadju-
vant chemoradiotherapy over neoadjuvant therapy has not
been established” [7]. Consequently, there is no standard
of care internationally, and established practice in many
countries often mirrors the outcomes of RCTs conducted,
with neoadjuvant chemotherapy practiced in the UK and
France, whereas a multimodality approach is more stand-
ard in the Netherlands, Australia, North America, Ireland
and Hong Kong [33]. The reports of the CROSS trial have
clearly established benchmark outcomes and accepted
toxicities that will result in broad application internation-
ally [15, 16]. Notwithstanding, the effects of the CROSS
regimen for adenocarcinoma are markedly inferior to its
impact on squamous cell cancer. This is highlighted in a
recent report on long term outcomes of CROSS, with a
median follow up of 84 months in surviving patients,
where the Hazards Ratio [HR 95% Confidence intervals
(CI)] was 0.48 (0.28–0.83; p = 0.008) for squamous cell
cancer and 0.73 (0.55–0.98; p = 0.038) for adenocarcinoma
[16]. Although significant, the margin of benefit for
adenocarcinoma compared with surgery does not establish
a standard of care based on the trial evidence, and lends
weight to the need to establish clear evidence whether the
addition of radiation to the multimodal regimen is super-
ior to systemic chemotherapy in the context of locally
advanced but resectable disease.
Both CROSS and the MAGIC trials were large studies
and adequately powered, neither however was powered
solely on adenocarcinoma of the oesophagus and junction.
In the CROSS trial the outcomes in the surgery only
group were superior to any previously reported outcomes
from RCTs, highlighting evolving major improvements in
the overall quality of oesophageal cancer treatment, in-
cluding staging, risk assessment, and all aspects of treat-
ment including operative outcomes. The Neo-AEGIS trial
is powered with a 10% difference chosen based on ap-
proximate estimates relating to available trial data for
adenocarcinoma alone, and an adjustment in addition for
the fact that MAGIC and CROSS were not contemporan-
eous trials. All measures of quality assurance that under-
pin outcomes in the modern high-volume oesophageal
centre will be applied in Neo-AEGIS, including state of
the art staging, quality assurance in radiation therapy and
pathology, and surgery only performed by high volume
surgeons. The trial is also unique in including all junc-
tional adenocarcinoma, including AEG III, which were ex-
cluded from CROSS, but are all grouped together with the
most recent TNM staging and denoted as “oesophageal”
tumours. The trial also uses a new international consensus
on defining oesophageal operative complications [26]. An
added value of the trial, not expounded in this publication,
is also the opportunity to collect tissue and blood samples
for storage in the bio bank for future international collab-
orative translational research, in particular targeted to-
wards response prediction and prognosis.
Additional files
Additional file 1 Appendix A: Description of data: copy of consent form
(DOCX 60 kb)
Additional file 2 Appendix B: - Description of data: Membership of
Trials Steering Committee (DOCX 22 kb)
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